CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Innocoll Holdings PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Innocoll Holdings PLC
Unit 9, Block D
Monksland Business Park
Phone: +353 906486834p:+353 906486834 Athlone, Ireland

On 3/16/2016, Innocoll AG and Innocoll Holdings PLC completed a European cross-border merger with Innocoll Holdings PLC continuing as the surviving entity. The merger resulted in Innocoll Holdings PLC becoming the publicly-traded parent of the Innocoll group of companies, carrying on the same business as that conducted by Innocoll AG prior to the merger.
This company is no longer actively traded on any major stock exchange.

Business Summary
Innocoll Holdings PLC is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically. Using its processes at its manufacturing facility, it derives and purifies bovine and equine collagen and then utilizes its technology platform to incorporate the purified collagen into its topical and implantable products. Its lead product candidates are XaraColl for the treatment of post-operative pain and Cogenzia for the treatment of diabetic foot infections. Its marketed products include CollaGUARD, Collatamp, Septocoll and RegenePro. It has initiated its Phase III efficacy trials for Cogenzia. On 7/24/2017, Gurnet Point L.P. acquired Innocoll Holdings PLC.
(Source: 20-F)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/201712/31/2016YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairperson of the Board Jonathan R.Symonds 58 5/1/2014 5/1/2014
President, Chief Executive Officer, Director Anthony P.Zook 55 12/7/2014 12/7/2014
Independent Vice Chairperson of the Board ShumeetBanerji 57 5/1/2014 5/1/2014
7 additional Officers and Directors records available in full report.

Business Names
Business Name
INNL
Innocoll Pharmaceuticals Ltd.
Innocoll, Inc.
Syntacoll GmbH

General Information
Number of Employees: 105 (As of 12/31/2016)
Outstanding Shares: 30,095,931 (As of 5/3/2017)
Shareholders: 20
Stock Exchange: NASD


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023